PCSK9 and sarcopenia: It highlights that long-term use of HMGCR inhibitors may increase muscle mass but compromise muscle function, and PCSK9 inhibitors could result in reduction of muscle mass, while NPC1L1 inhibitors are not associated with sarcopenia-related traits and may serve as viable alternatives to individuals with sarcopenia or those at an elevated risk.